Session » RA – Treatments Poster III: Safety and Outcomes
-
Abstract Number: 2351
Withdrawal of Conventional Synthetic Disease-Modifying Antirheumatic Drugs in the Sarilumab Open-Label EXTEND Study: Efficacy and Safety Analysis
-
Abstract Number: 2352
Real-World Distribution of Anti-Cyclic Citrullinated Peptide Concentrations and Impact on Treatment Patterns of Patients with Rheumatoid Arthritis
-
Abstract Number: 2353
ACPA Testing and Resultant Treatment Patterns in Patients with Rheumatoid Arthritis: Findings from US Community Rheumatology Practices
-
Abstract Number: 2354
Replication of a Prognostic Multivariable Prediction Model for Insufficient Clinical Response to Methotrexate in Early Rheumatoid Arthritis
-
Abstract Number: 2355
Antirheumatic Therapy Is Associated with Reduced Complement Activation in Rheumatoid Arthritis
-
Abstract Number: 2356
Antirheumatic Therapy Is Not Associated with Changes in Circulating N-terminal Pro-brain Natriuretic Peptide Levels in Patients with Active Rheumatoid Arthritis
-
Abstract Number: 2357
Methotrexate Liver Toxicity in a Large Randomized Controlled Trial
-
Abstract Number: 2359
High Body Mass Index Shortens Retention of Tumor Necrosis Factor-α Blocker Treatment in Rheumatoid Arthritis
-
Abstract Number: 2360
Safety of Biological DMARD in Patients with Interstitial Lung Disease from a Chilean Cohort of Patients with Rheumatoid Arthritis
-
Abstract Number: 2361
Early Treatment of Rheumatoid Arthritis with Disease-Modifying Anti-Rheumatic Drugs at < 3 versus 3-6 Months from Onset of Symptoms: Results from a Cohort of Hispanics from Puerto Rico
-
Abstract Number: 2362
Associations of Disease-Modifying Anti-Rheumatic Drug (DMARD) Adherence with Time to First Biologic and Cycle Time on DMARDs, and Healthcare Utilization/Cost in a New RA Patient Cohort
-
Abstract Number: 2363
Influence of the Clinical Characteristics and Different Genetic Polymorphisms Related to MTX, on the Efficacy and Safety in Patients with RA Treated with MTX in Monotherapy
-
Abstract Number: 2364
Multi-center Analyses on 518 Cases with Rheumatoid Arthritis Developing Lymphoproliferative Disorders (RA-LPD): The Prognostic Factors and the Influence of Anti-rheumatic Drugs on LPD Development
-
Abstract Number: 2365
Risk of Diabetes Treatment Switching or Intensification Associated with Use of Abatacept versus Other Biologic Drugs in Patients with Rheumatoid Arthritis and Diabetes Mellitus
-
Abstract Number: 2367
The Effect of DMARDs on Cardiovascular Outcomes in Rheumatoid Arthritis: A Systematic Literature Review
-
Abstract Number: 2368
Risk of Diverticulitis and Gastro-Intestinal Perforation in Rheumatoid Arthritis Treated with Tocilizumab Compared to Rituximab and Abatacept: A Prospective Propensity-matched Cohort Study
-
Abstract Number: 2369
Treatment Patterns with Disease Modifying Anti-rheumatic Drugs in United States Veterans with Newly Diagnosed Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis
-
Abstract Number: 2370
Discontinuation of Disease Modifying Drugs in Patients with Incident Rheumatoid Arthritis
-
Abstract Number: 2371
Risk of Malignancies Across Biologic Classes in Rheumatoid Arthritis: Analysis of a National Claim Database
-
Abstract Number: 2372
Post-Approval Comparative Safety Study of Tofacitinib and Biologic DMARDs: Five‑Year Results from a US-based Rheumatoid Arthritis Registry
-
Abstract Number: 2373
Two Decades of Changes in RA Treatment and Disease Outcomes from the United States
-
Abstract Number: 2374
MRI of the Wrist in Early Rheumatoid Arthritis After 1-year Treat-to-target Strategy
-
Abstract Number: 2375
Safety of Baricitinib Under Clinical Settings in Patients with Rheumatoid Arthritis, Using Data from All-Case Post-marketing Surveillance and Spontaneous Reports
-
Abstract Number: 2376
Modifiable Factors Associated with Response to Treatment in Early Rheumatoid Arthritis
-
Abstract Number: 2377
Methotrexate Discontinuation and Dose Decreases After Therapy with Tocilizumab: Results from the Corrona Rheumatoid Arthritis Registry
-
Abstract Number: 2378
Comparative Analysis of Clinical, Laboratory and Therapeutic Strategies Among Blacks with Rhupus, SLE and RA
-
Abstract Number: 2379
High Initial Methotrexate Dose Is Not Associated with an Increased Risk of Liver Toxicity in Korean Patients with Rheumatoid Arthritis
-
Abstract Number: 2380
Improving Depression by Joint Surgery in Established Rheumatoid Arthritis; Results from Multicenter Prospective Cohort Study for Evaluation of Joint Surgery on Patient’s Reported Outcome
-
Abstract Number: 2382
Relationships Between DAS28 Response and Clinical, Functional and Radiographic Outcomes in Year 2 of the COMET Study of Etanercept in Patients with Rheumatoid Arthritis
-
Abstract Number: 2383
Treatment for Rheumatoid Arthritis After Methotrexate-associated Lymphoproliferative Disorder Developed
-
Abstract Number: 2384
Yoga Improves Fatigue and Mental Health in Rheumatoid Arthritis: Preliminary Results of a Randomized Controlled Trial
-
Abstract Number: 2385
Efficacy and Safety of Chinese Herbal Medicine Biqi Capsule Combined with Methotrexate in Patients with Rheumatoid Arthritis: A Pilot Study
-
Abstract Number: 2386
Consensus Statement and Recommendations on Methotrexate Use in Combined Therapy with Biological or Targeted Synthetic Disease Modifying Drugs in Patients with Rheumatoid Arthritis
-
Abstract Number: 2387
Management of Patients with Incident Rheumatoid Arthritis in Rheumatology Clinical Practice
-
Abstract Number: 2388
Patient Characteristics Associated with Long Term Glucocorticoid Use in a Commercially Insured Incident RA Cohort
-
Abstract Number: 2389
Treat to Target by Specific Cytokine Interdiction: Multiple Biomarker Disease Activity Test Deconstructed
-
Abstract Number: 2390
Prediction of Disease Relapses by Multi-biomarker Disease Activity Score and Autoantibody Status in RA Patients Tapering DMARD Treatment in Stable Remission
-
Abstract Number: 2391
Effect of Biologics on the Hemoglobin A1c in a Population of Rheumatoid Arthritis Patients
-
Abstract Number: 2392
The Effectiveness of anti-IL-6 Therapy to Elderly-onset Rheumatoid Arthritis
-
Abstract Number: 2393
Risk of Thromboembolism with Janus Kinase Inhibitors: A Systematic Review and Meta-Analysis of Randomized Placebo Controlled Trials
-
Abstract Number: 2394
Use and Influence of Biologic/Janus Kinase Monotherapy Among Recently Switched Rheumatoid Arthritis Patients: Results from an Annual National Patient Chart Audit
-
Abstract Number: 2396
DNA Methylation of the Dual Specificity Phosphatase 22 (DUSP22) Gene Promoter in Plasma and Medication Use in Rheumatoid Arthritis (RA)
-
Abstract Number: 2397
Skin Lesions as a Side Effect of anti-IL6 Therapy: Transcriptome Analysis of Peripheral Blood Shows a Risk of Paradoxical Neutrophil Activation and Exacerbation of Skin Ulcer
-
Abstract Number: 2398
Prevalence of Anxiety and Depression in a Cohort of Patients with Rheumatic Diseases on Biological Infusions
-
Abstract Number: 2399
Changes in the Initial Usage Pattern of Biologic Disease-modifying Antirheumatic Drugs in Rheumatic Diseases During the past Twelve Years: A Real-world Setting Analysis
-
Abstract Number: 2401
Enhanced Methotrexate Polyglutamation in Japanese as Compared to Caucasian Rheumatoid Arthritis Patients Starting Methotrexate
-
Abstract Number: 2402
Which Factors Influence Achievement of Treatment Satisfaction in Rheumatoid Arthritis?
-
Abstract Number: 2403
Adverse Events of Special Interest in Patients with Rheumatoid Arthritis Treated with Peficitinib in Asian Population: Pooled Safety Findings
-
Abstract Number: 2404
Does Combined Therapy Affects Adherence in Rheumatoid Arthritis?
-
Abstract Number: 2405
Protein Biomarkers Predicting the Response to IFX+MTX+LEF Treatment in Patients with Rheumatoid Arthritis
-
Abstract Number: 2406
Hepatobiliary Events in >5000 Patients with Inflammatory Arthritis Treated with Biosimilar or Originator Etanercept in Routine Care, Results from the Danish Nationwide DANBIO Registry
-
Abstract Number: 2407
The Safety Profile of Upadacitinib in Japanese Patients with Rheumatoid Arthritis